501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers

BACKGROUND: Bezlotoxumab (BEZ) was approved in October 2016 for the prevention of recurrent C. difficile (rCDI) infection in patients receiving standard-of-care (SoC) antibiotic therapy for active CDI who are at high risk for CDI recurrence. Presently, there are little real-world data on recurrence...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Hengel, Richard L, Ritter, Timothy E, Nathan, Ramesh V, Anglen, Lucinda J Van, Schroeder, Claudia P, Marcella, Stephen, Garey, Kevin W
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6253562/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.510
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars